Manuela Curescu 1
1 University of Medicine and Pharmacy Timisoara, Romania
Abstract
Background. There are 2 billion people infected worldwide, with approximately 5% of the
world’s population (or 350 million people) being carriers of chronic hepatitis B. [2] Worldwide, chronic hepatitis B is the 10th leading cause of death. HBeAg-negative chronic hepatitis B patients show a lower sustained response to interferon (IFN). Methods. We present two clinical cases of chronic HBeAg negative patients who received several treatments, from standard interferon alpha 2a to nucleoside analogues. Results. In a number of cases, the treatment of chronic HBeAg negative chronic hepatitis B can be a real challenge for the physicians and it is possible that prolonged Peginterferon therapy or addition of nucleot(s) ides analogues may increase the response rate.